NICE Guidance Links Cost-Effectiveness of Osteoporosis Treatments with Fracture Risk

Drug Industry Daily
A A
New guidance from the UK’s National Institute of Health and Care Excellence links the cost-effectiveness of different bisphosphonate medications for osteoporosis with a patient’s 10-year risk of bone fractures.

To View This Article:

Login

Subscribe To Drug Industry Daily